Page last updated: 2024-10-29

ifosfamide and Infection

ifosfamide has been researched along with Infection in 13 studies

Research Excerpts

ExcerptRelevanceReference
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."9.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
" Based on the limited clinical impact and the high incidence of rhGM-CSF-related toxicity that required growth factor discontinuation, the routine administration of rhGM-CSF to prevent neutropenia and infection after ifosfamide-based chemotherapy for GCT patients is not recommended."5.08Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. ( Bajorin, DF; Bokemeyer, C; Bosl, GJ; Demetri, GD; Einhorn, LH; Kantoff, PW; Nichols, CR; Schmoll, HJ, 1995)
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."5.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
"Grade 3 and 4 infections occurred four times more frequently in the dose-dense arm."2.75Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. ( Chott, A; Drach, J; Fridrik, MA; Geissler, D; Greil, R; Hausmaninger, H; Krieger, O; Lang, A; Michlmayr, G; Oberaigner, W; Ulsperger, E, 2010)
" After adjusting for body size, AUC0-6 and Cmax were positively related to dose (P = 0."2.71Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. ( Beane, C; Boddy, AV; Brennan, B; Chisholm, JC; Cole, M; Elsworth, AM; Errington, J; Glaser, A; Hale, J; Hemsworth, S; Howe, K; Jenner, G; McDowell, H; Nicholson, J; Parry, A; Pearson, AD; Pinkerton, R; Pritchard-Jones, K; Veal, GJ; Waters, F; Wright, Y, 2005)
"Fungal, viral, and nosocomial infections were uncommon."1.35Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. ( Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM, 2008)
"Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)."1.33IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005)
"We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC."1.32Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004)
" Poor performance status and prior radiotherapy were risk factors for fatal adverse effects."1.30[Treatment of advanced testicular cancer and toxicity of chemotherapy]. ( Kawakita, M; Matsuda, T; Terachi, T; Yoshida, O, 1999)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19902 (15.38)18.7374
1990's3 (23.08)18.2507
2000's7 (53.85)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fridrik, MA1
Hausmaninger, H1
Lang, A1
Drach, J1
Krieger, O1
Geissler, D1
Michlmayr, G1
Ulsperger, E1
Chott, A1
Oberaigner, W1
Greil, R1
Caglar, K1
Kinalp, C1
Arpaci, F1
Turan, M1
Saglam, K1
Ozturk, B1
Komurcu, S1
Yavuz, I1
Yenicesu, M1
Ozet, A1
Vural, A1
De Rosa, L1
Anghel, G1
Pandolfi, A1
Riccardi, M1
Amodeo, R1
Majolino, I1
Abali, H1
Oyan, B1
Koc, Y1
Kars, A1
Barista, I1
Uner, A1
Turker, A1
Demirkazik, F1
Tekin, F1
Tekuzman, G1
Kansu, E1
Veal, GJ1
Cole, M1
Errington, J1
Parry, A1
Hale, J1
Pearson, AD1
Howe, K1
Chisholm, JC1
Beane, C1
Brennan, B1
Waters, F1
Glaser, A1
Hemsworth, S1
McDowell, H1
Wright, Y1
Pritchard-Jones, K1
Pinkerton, R1
Jenner, G1
Nicholson, J1
Elsworth, AM1
Boddy, AV1
Jathavedam, A1
Feldman, DR1
Ishill, N1
Turkula, S1
Patil, S1
Bosl, GJ2
Motzer, RJ1
Weinstock, DM1
Bajorin, DF1
Nichols, CR1
Schmoll, HJ1
Kantoff, PW1
Bokemeyer, C1
Demetri, GD1
Einhorn, LH2
Urban, C1
Benesch, M1
Pakisch, B1
Lackner, H1
Kerbl, R1
Schwinger, W1
Oberbauer, R1
Kawakita, M1
Matsuda, T1
Terachi, T1
Yoshida, O1
García-Rayo, S1
Pérez-Calvo, J1
Martín-Algarra, S1
Martínez-Monge, R1
Fernández-Hidalgo, O1
Subirá, L1
Martínez-Aguillo, M1
Rebollo, J1
Azinovic, I1
Brugarolas, A1
Lee, EJ1
Petroni, GR1
Schiffer, CA1
Freter, CE1
Johnson, JL1
Barcos, M1
Frizzera, G1
Bloomfield, CD1
Peterson, BA1
Bramwell, VH1
Mouridsen, HT1
Santoro, A1
Blackledge, G1
Somers, R1
Thomas, D1
Sylvester, R1
Van Oosterom, A1
Loehrer, PJ1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma[NCT00517894]0 participants Expanded AccessNo longer available
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193]Phase 220 participants (Anticipated)Interventional2006-08-31Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494]Phase 2134 participants (Actual)Interventional1992-05-31Completed
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473]Phase 2100 participants (Anticipated)Interventional2014-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for ifosfamide and Infection

ArticleYear
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001

Trials

7 trials available for ifosfamide and Infection

ArticleYear
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
    Annals of hematology, 2010, Volume: 89, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha

2010
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat

2005
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma;

1995
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
    Journal of neuro-oncology, 1998, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che

1998
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
    Bone marrow transplantation, 2001, Volume: 28, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin;

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections;

1986

Other Studies

6 other studies available for ifosfamide and Infection

ArticleYear
Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2002, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Alkyla

2002
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm

2004
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F

2005
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H

2008
[Treatment of advanced testicular cancer and toxicity of chemotherapy].
    Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Germinoma; Humans;

1999
Ifosfamide chemotherapy for pancreatic carcinoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam

1986